WO1995026980A3 - Haptenated peptides and uses thereof - Google Patents

Haptenated peptides and uses thereof Download PDF

Info

Publication number
WO1995026980A3
WO1995026980A3 PCT/US1995/004121 US9504121W WO9526980A3 WO 1995026980 A3 WO1995026980 A3 WO 1995026980A3 US 9504121 W US9504121 W US 9504121W WO 9526980 A3 WO9526980 A3 WO 9526980A3
Authority
WO
WIPO (PCT)
Prior art keywords
urushiol
haptenated
peptides
poison
haptens
Prior art date
Application number
PCT/US1995/004121
Other languages
French (fr)
Other versions
WO1995026980A2 (en
Inventor
Charles J Hackett
Julia L Greenstein
Malcolm L Gefter
Kurt Jeff Wilson
Cohava Gelber
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Priority to AU22383/95A priority Critical patent/AU2238395A/en
Publication of WO1995026980A2 publication Critical patent/WO1995026980A2/en
Publication of WO1995026980A3 publication Critical patent/WO1995026980A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MHC-binding carrier peptides linked to catechol derivatives are provided which are recognized by urushiol-specific T lymphocytes. The compounds are useful in therapeutic compositions and methods for desensitizing individuals against contact sensitivity to haptens, such as urushiol of poison ivy/poison oak.
PCT/US1995/004121 1994-04-01 1995-03-30 Haptenated peptides and uses thereof WO1995026980A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22383/95A AU2238395A (en) 1994-04-01 1995-03-30 Haptenated peptides and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22220694A 1994-04-01 1994-04-01
US08/222,206 1994-04-01
US38364595A 1995-02-06 1995-02-06
US08/383,645 1995-02-06

Publications (2)

Publication Number Publication Date
WO1995026980A2 WO1995026980A2 (en) 1995-10-12
WO1995026980A3 true WO1995026980A3 (en) 1995-12-07

Family

ID=26916551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/004121 WO1995026980A2 (en) 1994-04-01 1995-03-30 Haptenated peptides and uses thereof

Country Status (3)

Country Link
AU (1) AU2238395A (en)
CA (1) CA2186873A1 (en)
WO (1) WO1995026980A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168456T3 (en) * 1995-01-16 2002-06-16 North Sydney Area Health Serv PEPTIDES AFFECTING T-LYMPHOCYTES
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
IL127332A0 (en) 1996-06-07 1999-09-22 Zeneca Ltd Peptide derivatives
EP0960119B1 (en) * 1996-06-11 2008-09-17 Northern Sydney and Central Coast Area Health Service T cell antigen receptor peptides
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
GB2348808B (en) * 1998-01-09 2003-03-19 Circassia Ltd Methods and compositions for desensitisation
ES2527760T3 (en) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
JP2003521448A (en) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ Synthetic peptides and methods of use for treating autoimmune diseases
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (en) * 1998-11-12 2002-10-09 Yeda Res & Dev Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US7053043B1 (en) 1999-07-23 2006-05-30 Yeda Research And Development Co.Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ES2349033T3 (en) 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. PROCEDURES FOR MEASURING THE ACTIVITY OF GLATIRAMER ACETATE.
WO2003047618A2 (en) * 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
GB2440529B (en) * 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
CN110801013B (en) * 2019-11-19 2023-03-31 西北农林科技大学 Method for preparing non-allergic raw lacquer or urushiol by biochemical method and product thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428965A (en) * 1979-05-31 1984-01-31 The University Of Mississippi Tolerizing and desensitizing compounds, compositions and methods of treatment against dermatological conditions caused by allergens from plants and trees of the Anacardiaceae and Ginkgoaceae families
WO1992007952A1 (en) * 1990-10-30 1992-05-14 Immulogic Pharmaceutical Corporation Peptide binding assays with mhc antigens
WO1992011859A1 (en) * 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428965A (en) * 1979-05-31 1984-01-31 The University Of Mississippi Tolerizing and desensitizing compounds, compositions and methods of treatment against dermatological conditions caused by allergens from plants and trees of the Anacardiaceae and Ginkgoaceae families
WO1992007952A1 (en) * 1990-10-30 1992-05-14 Immulogic Pharmaceutical Corporation Peptide binding assays with mhc antigens
WO1992011859A1 (en) * 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADORINI L.: "Inhibition of T Cell Activation by MHC Blockade: A Possible Strategy for Immunointervention in Autoimmune Diseases", J. AUTOIMMUNITY (SUPPLEMENT A), vol. 5, pages 73 - 81 *
NAZIH A. ET AL.: "Bihaptens with 5- and 6-Methyl-Substituted Alkylcatechols and Methylene Lactone Functional Groups: Tools for Hapten (Allergen or Tolerogen)-Protein Interaction Studies", CHEM. RES. TOXICOL., vol. 6, no. 2, pages 216 - 222 *

Also Published As

Publication number Publication date
AU2238395A (en) 1995-10-23
WO1995026980A2 (en) 1995-10-12
CA2186873A1 (en) 1995-10-12

Similar Documents

Publication Publication Date Title
WO1995026980A3 (en) Haptenated peptides and uses thereof
AU6665090A (en) Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
IE44749L (en) Cyclopeptide
IE780729L (en) Excipient based on cellulose
NL190624C (en) Gas seal device for an axle.
AU4861890A (en) Alkylated polyethylenimine derivatives, process for their preparation, their use as pharmaceuticals and pharmaceutical preparations
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
IE44767L (en) Antibiotic composition
AU5346179A (en) Amino acid derivatives as antihypertensives
IE811275L (en) Vinblastines
AU2915900A (en) Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine
AU3152689A (en) 1,3,4,5-Tetrahydrobenz(c,d) indoles
AU5195593A (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
AU1274395A (en) Indoline derivatives, method of preparation and their use as pharmaceuticals
AU2974189A (en) Pharmaceutical compositions containing lactams, new substituted lactams and processes for the preparation thereof
AU1170399A (en) Spheroids containing tiagabine, preparation process and pharmaceutical comp ositions
AU4439289A (en) A composition containing an extract obtained by a water-containing organic solvent, and a process for preparing the same
AU538478B2 (en) N-carboxamido(thiocarboxamido) quinoline, indole benzoxazine and benzthiazine derivatives
ES8800915A1 (en) Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase.
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
AU6534896A (en) Package as well as a plate and a box suitable for such a package
CA1027844A (en) System for recovering and condensing vapors
AU622010B2 (en) Substituted 1,8-naphthyridines
AU577345B2 (en) Indolophenanthridines
AR004476A1 (en) BICYCLE COMPOUNDS, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2186873

Country of ref document: CA

122 Ep: pct application non-entry in european phase